Abstract
Collagen-induced arthritis in mice has been widely used to address questions of disease pathogenesis and to validate therapeutic targets for human rheumatoid arthritis. Arthritis is normally observed about 3 wk after immunization with autologous or heterologous type II collagen in complete Freund’s adjuvant and susceptibility to the disease is strongly associated with major histocompatibility complex class II genes. The development of collagen-induced arthritis is associated with strong T- and B-cell responses to type II collagen and the chief pathological features of the disease include a proliferative synovitis with infiltration of polymorphonuclear and mononuclear cells, pannus formation, cartilage degradation, erosion of bone and fibrosis. Proinflammatory cytokines, such as tumor necrosis factor-α and interleukin—1β, are abundantly expressed in the arthritic joints of mice with collagen-induced arthritis and, as in human rheumatoid arthritis, blockade of these molecules is effective in reducing the severity of disease.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Elliott, M. J., Maini, R. N., Feldmann, M., (1993) Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumour necrosis factor α. Arth. Rhuem. 36, 1681–1690.
Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Treatment with a chimaeric monoclonal antibody to tumour necrosis factor α suppresses disease activity in rheumatoid arthritis: results of a multi-centre, randomised, double blind trial. Lancet 344, 1105–1110.
Elliott, M. J., Maini, R. N., Feldmann, M., et al. (1994) Repeated therapy with a monoclonal antibody to tumour necrosis factor α in patients with rheumatoid arthritis. Lancet 344, 1125–1127.
Moreland, L. W., Baumgartner, S. W., Schiff, M. H., et al. (1997) Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. ew Engl. J. Med. 337, 141–147.
Weinblatt, M. E., Kremer, J. M., Bankhurst, A. D., Bulpitt, K. J., Fleischmann, R. M., Fox, R. I., et al. (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Engl. J. med 340, 253–259.
Williams, R. O. (1998) Rodent models of arthritis: relevance for human disease. Clin. Exp. Immunol. 114, 330–332.
Ranges, G. E., Sriram, S., and Cooper, S. M. (1985) Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J. Exp. Med. 162, 1105–1110.
Hom, J. T., Butler, L. D., Riedl, P. E., and Bendele, A. M. (1988) The progression of the inflammation in established collagen-induced arthritis can be altered by treatments with immunological or pharmacological agents which inhibit T cell activities. Eur. J. Immunol. 18, 881–888.
Webb, L. M., Walmsley, M. J., and Feldmann, M. (1996) Prevention and amelioratrion of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2. Eur. J. Immunol. 26, 2320–2328.
Malfait, A.-M., Butler, D. M., Presky, D. H., Maini, R. N., Brennan, F. M., and Feldmann, M. (1998) Blockade of IL-12 during the induction of collagen-induced arthritis (CIA) markedly attenuates the severity of the arthritis. Clin. Exp. Immunol. 111, 377–383.
Holmdahl, R., Jansson, L., Larsson, E., Rubin, K., and Klareskog, L. (1986) Homologous type II collagen induces chronic and progressive arthritis in mice. Arth. Rheum. 29, 106–113.
Boissier, M. C., Feng, X. Z., Carlioz, A., Roudier, R., and Fournier, C. (1987) Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. Ann. Rheum. Dis. 46, 691–700.
Malfait, A. M., Williams, R. O., Malik, A. S., Maini, R. N., and Feldmann, M. (2001) Chronic relapsing homologous collagen-induced arthritis in DBA/1 mice as a model for testing disease-modifying and remission-inducing therapies. Arth. Rheum. 44, 1215–1224.
Huang, J. C., Vestberg, M., Minguela, A., Holmdahl, R., and Ward, E. S. (2004) Analysis of autoreactive T cells associated with murine collagen-induced arthritis using peptide-MHC multimers. Int. Immunol. 16, 283–293.
Holmdahl, R., Andersson, M. E., Goldschmidt, T. J., et al. (1989) Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity. APMIS 97, 575–584.
Trentham, D. E. (1982) Collagen arthritis as a relevant model for rheumatoid arthritis: evidence pro and con. Arth. Rheum. 25, 911–916.
Marinova-Mutafchieva, L., Williams, R. O., Mason, L. J., Mauri, C., Feldmann, M., and Maini, R. N. (1997) Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin. Exp. Immunol. 107, 507–512.
Thorbecke, G. J., Shah, R., Leu, C. H., Kuruvilla, A. P., Hardison, A. M., and Palladino, M. A. (1992) Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice. Proc. Natl. Acad. Sci. USA 89, 7375–7379
Williams, R. O., Feldmann, M., and Maini, R. N. (1992) Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA 89, 9784–9788.
Piguet, P. F., Grau, G. E., Vesin, C., Loetscher, H., Gentz, R., and Lesslauer, W. (1992) Evolution of collagen arthritis in mice is arrested by treatment with antitumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 77, 510–514.
Geiger, T., Towbin, H., Cosenti-Vargas, A., Zingel, O., Arnold, J., Rordorf, C., and Vosbeck, K. (1993) Neutralization of interleukin-1β activity in vivo with a monoclonal antibody alleviates collagen-induced arthritis in DBA/1 mice and prevents the associated acute-phase response. Clin. Exp. Rheumatol. 111, 515–522.
Wooley, P. H., Dutcher, J., Widmer, M. B., and Gillis, S. (1993) Influence of a recombinant human soluble tumour necrosis factor receptor Fc fusion protein on type II collagen-induced arthritis in mice. J. Immunol. 151, 6602–6607.
Van den Berg, W. B., Joosten, L. A., Helsen, M., and van de Loo, F. A. (1994) Amelioration of established murine collagen-induced arthritis with anti-IL-1 treatment. Clin. Exp. Immunol. 95, 237–243.
Williams, R. O., Ghrayeb, J., Feldmann, M., and Maini, R. N. (1995) Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84, 433–439.
Joosten, L. A. B., Helen, M. M. A., van de Loo, F. A. J., and Van den Berg, W. B. (1996) Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNFα, anti-IL-1α/β, and IL-1Ra. Arth. Rheum. 39, 797–80
Miller, E. J. (1972) Structural studies on cartilage collagen employing limited cleavage and solubilization with pepsin. Biochemistry 11, 4903–4909.
Herbage, D., Bouillet, J., and Bernengo, J. C. (1977) Biochemical and physiochemical characterization of pepsin-solubilized type-II collagen from bovine articular cartilage. Biochem. J. 161, 303–312.
Ratcliffe, A., Doherty, M., Maini, R. N., and Hardingham, T. E. (1988) Increased concentrations of proteoglycan components in the synovial fluids of patients with acute but not chronic joint disease. Ann. Rheum. Dis. 47, 826–832.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc., Totowa, NJ
About this protocol
Cite this protocol
Williams, R.O. (2007). Collagen-Induced Arthritis in Mice. In: Cope, A.P. (eds) Arthritis Research. Methods in Molecular Medicine, vol 136. Humana Press. https://doi.org/10.1007/978-1-59745-402-5_14
Download citation
DOI: https://doi.org/10.1007/978-1-59745-402-5_14
Publisher Name: Humana Press
Print ISBN: 978-1-58829-918-5
Online ISBN: 978-1-59745-402-5
eBook Packages: Springer Protocols